[Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection].

Abstract

OBJECTIVE:

To evaluate the efficacy of bismuth-based quadruple therapy as the first-line treatment for H.pylori infection.

METHODS:

A total of 136 patients with H.pylori related peptic ulcer or chronic gastritis were randomized into two groups: 67 patients in bismuth-based quadruple group received esomeprazole 20 mg, clarithromycin 0.5 g,amoxicillin 1.0 g,and bismuth potassium citrate 220 mg for 7 d; 69 patients in standard triple group received esomeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1.0 g for 7 d. Outcome of eradication therapy was assessed by (14)C-UBT. On ITT and PP analysis, calculating the cost-effectiveness ratio (C/E) and the incremental cost-effectiveness ratio (delta C/delta E).

RESULT:

On ITT and PP analysis, the eradication rates of the quadruple therapy group were 82.09% and 88.71%, and those of the triple therapy group were 66.67% and 73.02% (P<0.05). The cost-effectiveness ratio of two groups was 4.15 and 4.82; The incremental cost-effectiveness ratio of quadruple therapy group was 1.02 as against triple therapy group.

CONCLUSION:

Compared to the standard triple therapy regimen, the bismuth-containing quadruple therapy regimen has higher eradication rate and cost-effectiveness, which can be recommended as the fist-line treatment for H.pylori infection.

• Authors: Mei-hua Xu, Gui-ying Zhang, Chang-juan Li
• Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences (Zhejiang Da Xue Xue Bao Yi Xue Ban) Vol. 40 Issue 3 Pg. 327-31 (05 2011) ISSN: 1008-9292 [Print] China
• PMID: 21671496 (Publication Type: Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Bacterial Agents
• Anti-Ulcer Agents
• Bismuth

Topics

• Adult
• Anti-Bacterial Agents (administration & dosage, economics, therapeutic use)
• Anti-Ulcer Agents (administration & dosage, economics, therapeutic use)
• Bismuth (administration & dosage, economics, therapeutic use)
• Cost-Benefit Analysis
• Drug Therapy, Combination (economics)
• Female
• Follow-Up Studies
• Helicobacter Infections (drug therapy)
• Humans
• Male
• Middle Aged
• Treatment Outcome